Currently, there are 26.45M common shares owned by the public and among those 16.89M shares have been available to trade.
The company’s stock has a 5-day price change of -93.85% and -88.57% over the past three months. SYRS shares are trading -97.45% year to date (YTD), with the 12-month market performance down to -93.37% lower. It has a 12-month low price of $0.25 and touched a high of $8.17 over the same period. SYRS has an average intraday trading volume of 1.44 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -90.15%, -89.89%, and -95.53% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Syros Pharmaceuticals Inc (NASDAQ: SYRS) shares accounts for 49.10% of the company’s 26.45M shares outstanding.
It has a market capitalization of $5.03M and a beta (3y monthly) value of 1.50. The earnings-per-share (ttm) stands at -$3.03. Price movements for the stock have been influenced by the stock’s volatility, which stands at 28.77% over the week and 18.24% over the month.
Earnings per share for the fiscal year are expected to increase by 73.32%, and -32.26% over the next financial year.
Looking at the support for the SYRS, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on November 04, 2020, with the firm’s price target at $11-$15. Alliance Global Partners coverage for the Syros Pharmaceuticals Inc (SYRS) stock in a research note released on September 22, 2020 offered a Buy rating with a price target of $18. Wedbush was of a view on January 17, 2020 that the stock is Neutral, while JMP Securities gave the stock Mkt Outperform rating on March 08, 2019, issuing a price target of $18. Oppenheimer on their part issued Outperform rating on February 14, 2019.
